NCT01096472View on ClinicalTrials.gov

Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Tinea Pedis
Interventions
DRUG

LAS41003

Once daily

DRUG

LAS189961

Once daily

DRUG

LAS189962

Once daily

Trial Locations (2)

10961

Investigational Site #2, Berlin

20095

Investigational Site #1, Hamburg

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT01096472 - Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis | Biotech Hunter | Biotech Hunter